Overview

* Tenon Medical ( TNON ) Q3 revenue grows 32% yr/yr to $1.17 mln, missing analysts' expectations

* Net loss for Q3 2025 was $3.3 mln, slightly higher than Q3 2024

* Company raised $2.85 mln in PIPE financing post-Q3 to fund growth

Outlook

* Company plans SImmetry+ alpha launch in Q4 2025

* Tenon Medical ( TNON ) aims for sustained growth via portfolio diversification and commercial expansion

* Company raised $2.85 mln in PIPE financing to fund growth initiatives

Result Drivers

* PROCEDURE VOLUME - Record Catamaran procedure volumes and SImmetry sales drove revenue growth, per CEO Steve Foster

* PORTFOLIO EXPANSION - Integration of SiVantage acquisition expanded product offerings and commercial reach

* GROSS MARGIN IMPROVEMENT - Higher revenue helped absorb fixed overhead costs, improving gross margin to 66%

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $1.17 $1.37

Revenue mln mln (2

Analysts

)

Q3 Net -$3.34

Income mln

Q3 $4.17

Operatin mln

g

Expenses

Q3 -$3.39

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Tenon Medical Inc ( TNON ) is $2.88, about 55.1% above its November 12 closing price of $1.29

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)